8th TIL Therapies Summit 2026

Memo

With the first TIL Therapy now approved in both the US and Canada, and the field regrouping following a setback in Europe, this is a pivotal time for drug developers looking to address treatment-resistant solid tumors. Returning for its 8th year, the TIL Therapies Summit remains the go-to forum for this close-knit community, created with the mission to transform end-to-end TIL development and deliver best-in-class therapies to treat solid tumor indications with significant unmet needs. With more patients being treated than ever, this summit unites a global collective of biopharma, academic thought leaders and clinicians including Curacell, Junecell, Obsidian Therapeutics, AgonOx, as they share their cutting-edge research into engineered TIL, easier manufacturing, QC, Potency, clinical updates, regulatory updates, investment opportunities and more. URLs:Tickets: https://go.evvnt.com/3740042-2?pid=5569Brochure: https://go.evvnt.com/3740042-3?pid=5569 Date and Time: On Tue, 17 Nov 2026 08:00 - Thu, 19 Nov 2026 17:00 Venue Details: Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, Massachusetts, 02128, United States Category: Conferences | Science, Health and Medicine | Pharmaceuticals Prices:Full Access: Conference + 2 Workshops - Drug Developer: USD 4397.00,Conference + 1 Workshop - Drug Developer: USD 3748.00,Conference Only - Drug Developer: USD 3099.00,Full Access: Conference + 2 Workshops - Academic: USD 3797.00,Conference + 1 Workshop - Academic: USD 3248.00,Conference Only - Academic: USD 2699.00,Full Access: Conference + 2 Workshops - Service Provider: USD 5297.00,Conference + 1 Workshop - Service Provider: USD 4548.00,Conference Only - Service Provider: USD 3799.00 Speakers: Eric Chen, Founder and Chief Executive Officer, Achelois BioPharma, Andrew Weinberg, President and Chief Scientific Officer, AgonOx, Lucas Arruda, Chief Scientific Officer, CuraCell Holding, Jonas Batelson, Co-Founder and Chief Executive Officer, CuraCell Holding AB, Zhang Changfeng, Chief Exectuitive Officer, Hongzhou Huasai Biomedicine, Nicholas Restifo, Chief Medical Officer, Medici Therapeutics, Parameswaran Hari, Chief Development Officer, Obsidian Therapeutics, Therese Choquette, Chief Technical Officer, Tigen Pharma SA, Aaron Goldman, Operating Partner, BroadOak Capital, Mengmeng Tang, Vice President, Juncell Therapeutics, Karrie Wong, Vice President Research, KSQ Therapeutics, Anne-Laure Joly, Cell Therapy Development and Analyses, Scientific Lead, NEOGAP Therapeutics AB, Giridharan Ramsingh, Vice President, Clinical Science, Obsidian Therapeutics, Víctor Albarran Fernandez, Medical Oncologist and Researcher, Cell Therapy for Solid Tumors, FCRB-IDIBAPS, Jessica Chacon, Assistant Professor, Texas Tech University Health Sciences Center, Eduardo Davila, Chief Scientific Officer, Trampoline Pharma, Michael Lotze, Professor of Surgery, Immunology, University of Pittsburgh Department of Medicine, Udai Kammula, Director, Solid Tumor Cell Therapy Program, UPMC Hillman Cancer Center